Kanach Colin, Blusztajn Jan K, Fischer Andre, Delalle Ivana
Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Lifespan Academic Medical Center, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
Department of Pathology and Laboratory Medicine, Boston University School of Medicine, 670 Albany Street, Boston, MA 02118, USA.
Noncoding RNA. 2021 Feb 1;7(1):8. doi: 10.3390/ncrna7010008.
The neurological damage of Alzheimer's disease (AD) is thought to be irreversible upon onset of dementia-like symptoms, as it takes years to decades for occult pathologic changes to become symptomatic. It is thus necessary to identify individuals at risk for the development of the disease before symptoms manifest in order to provide early intervention. Surrogate markers are critical for early disease detection, stratification of patients in clinical trials, prediction of disease progression, evaluation of response to treatment, and also insight into pathomechanisms. Here, we review the evidence for a number of microRNAs that may serve as biomarkers with possible mechanistic insights into the AD pathophysiologic processes, years before the clinical manifestation of the disease.
阿尔茨海默病（AD）的神经损伤在出现痴呆样症状后被认为是不可逆的，因为隐匿的病理变化需要数年至数十年才会出现症状。因此，有必要在症状出现之前识别出有患该病风险的个体，以便进行早期干预。替代标志物对于疾病的早期检测、临床试验中患者的分层、疾病进展的预测、治疗反应的评估以及对发病机制的洞察都至关重要。在此，我们综述了一些 microRNA 作为生物标志物的证据，这些证据可能为 AD 病理生理过程提供机制性见解，且是在该疾病临床表现出现的数年之前。
